Use for general testing in contexts of compliance and/or abuse, primarily in the pain management population. Alternative testing strategies include Pain Management Drug Panel by High-Resolution Time-of-Flight or Tandem Mass Spectrometry and Enzyme Immunoassay, Urine (2007479) and Pain Management Drug Panel with Interpretation by High-Resolution Time-of-Flight or Tandem Mass Spectrometry and Enzyme Immunoassay, Urine (2009288).
Qualitative Enzyme Immunoassay/Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Transfer 4 mL each into two (2) ARUP Standard Transport Tubes urine with no additives or preservatives. (Min: 2 mL each)
Specimens exposed to multiple freeze/thaw cycles, Pharmaceutical preparation.
Ambient: 1 week; Refrigerated: 1 month; frozen: 3 years
|Drugs covered and range of cutoff concentrations|
|Ethyl Glucuronide||500 ng/mL|
|MDMA (Ecstasy)||500 ng/mL|
|THC (Cannabinoids)||20 ng/mL|
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies. Specimens for which drugs or drug classes are detected by the screen are reflexed to a second, more specific technology (GC/MS and or LC MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
For medical purposes only; not valid for forensic use.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
If the specimen screens positive, then Confirmation/Quantitation by GC/MS and/or LC-MS/MS will be added to confirm result. Additional charges apply.
80307; if reflexed, add 80321; 80325; 80345; 80346; 80348; 80349; 80353; 80354; 80358; 80359; 80361; 80362; 80365; 80367; 80368; 80369; 80372; 80373; 83992 (Reflexed Alt Code: G0480 )
|Component Test Code*||Component Chart Name||LOINC|
|0092191||Amphetamines, Urn, Screen||19348-2|
|0092192||Cocaine, Urn, Screen||19359-9|
|0092194||Phencyclidine, Urn, Screen||19661-8|
|0092195||THC, Urn, Screen||19292-2|
|0092196||Barbiturates, Urn, Screen||19276-5|
|0092197||Benzodiazepines, Urn, Screen||19284-9|
|0092198||Propoxyphene, Urn, Screen||19432-4|
|0092199||Methadone, Urn, Screen||19553-7|
|2005094||Opiates, Urn, Screen||19295-5|
|2005102||Oxycodone/Oxymorphone, Urn, Screen||58430-0|
|2007913||Ethyl Glucuronide Screen w/Rflx, Urine||58375-7|
|2012212||Screen, Urine Interpretation||54247-2|
|2012274||Buprenorphine, Urn, Screen||3415-7|
|2012279||Carisoprodol, Urn, Screen||10979-3|
|2012285||Fentanyl, Urn, Screen||11235-9|
|2012289||Meperidine, Urn, Screen||3746-5|
|2012295||Tapentadol, Urn, Screen||65807-0|
|2012298||Tramadol, Urn, Screen||19712-9|
|2012301||Zolpidem, Urn, Screen||33339-3|
- See individual components